Taaleri’s first bioindustry fund invests in Nordtreat, a company producing bio-based flame retardants
TAALERI BIOINDUSTRY PRESS RELEASE 22 NOVEMBER 2022 AT 9:15 (EET)
Taaleri’s first bioindustry fund invests in Nordtreat, a company producing bio-based flame retardants
Taaleri’s first bioindustry fund invests in Nordtreat, a Finnish company producing bio-based, environmentally friendly and non-harmful flame-retardants. The purpose of the investment is to strengthen Nordtreat's growth and expansion.
Founded in 2015, Nordtreat manufactures bio-based flame-retardant chemicals for building materials made from renewable raw materials. The company has developed and commercialized fire retardants, especially for wood construction. The products are based on the company's patented fire protection technology. Nordtreat's products replace traditional flame-retardants that contain compounds that are harmful to humans and the environment, such as boric acid, formaldehyde, and ammonia.
The investment is Taaleri Bioindustry I Fund’s second investment. The fund invests in industrial-scale production facilities and companies that can accelerate the scaling of bioindustry production. Products can be, for example, bio- and recycled fibers, organic fertilizers, functional biomaterials, and recycled materials to replace virgin products.
Taaleri Bioindustry I Fund complies with Article 9 of the EU Sustainable Finance Disclosure Regulation and is as such a so called dark green fund that only makes sustainable investments in projects that, for example, contribute substantially to climate change mitigation. The fund has raised over EUR 100 million and continues fundraising. The state-owned special-assignment companyFinnish Climate Fund is the fund’s anchor investor.
In February 2022, Taaleri made an investment of one million euros in Nordtreat from its own balance sheet. This investment will be acquired by the fund in addition to the investment made now.
“We are very happy to continue our partnership with Nordtreat. We see great potential for the company’s international growth. We believe that the demand for sustainable fire retardants will grow in the international building product industry, as the responsibility requirements of developers become stricter”, says Tero Saarno, Director of Taaleri Bioindustry.
“Taaleri Bioindustry I Fund’s investment enables the scaling of production and supply of Nordtreat’s bio-based flame-retardant technology to a growing industrial customer base globally. In the past twelve months, we have been able to accelerate the commercialisation of our technology to two new industrial segments, cellulose insulation and kraft paper, as well as solidifying our position as a preferred supplier for flame-retardant solutions for the wood industry through Taaleri’s previous investment,” says Aki Borgentrop, CEO of Nordtreat.
Taaleri's vision is to be a Nordic pioneer in alternative investments focusing on sustainability. We use capital and our expertise to build a better future, and in addition to bioindustry projects, we promote e.g. wind and solar power.
For further information, please contact:
Tero Saarno, director, Taaleri Bioindustry, +358 50 373 1923, tero.saarno@taaleri.com
Aki Borgentrop, CEO, Nordtreat, +358 400 366 801
Taaleri in brief
Taaleri is a Nordic investment and asset manager with an emphasis on renewable energy and other alternative investments. We channel capital towards economically profitable undertakings that have a lasting positive impact on the environment and society. We combine capital with talent, expertise, entrepreneurship, and a bold sense of purpose. We are a signatory of the UN Principles for Responsible Investment (UNPRI) since 2010, and we joined the Net Zero Asset Managers initiative in 2021. Taaleri’s vision is to be a Nordic forerunner in alternative investments focusing on sustainability.
Taaleri has two business segments: Private Asset Management and Strategic Investments. Private Asset Management consists of renewable energy, real estate and bioindustry businesses. The Strategic Investments segment includes Garantia Insurance Company Ltd.
Taaleri has EUR 2.5 bn of assets under management in its private equity funds and co-investments. The company has approximately 120 employees. Taaleri Plc is listed on Nasdaq Helsinki.
Nordtreat in brief
Nordtreat is growth company in the chemicals industry founded in 2015. The company is specialised in manufacturing of bio-based environmentally friendly flame-retardants. Nordtreat’s patented technology is utilised in fire protection of sustainable construction products, especially in public and apartment buildings.
The company employs more than 30 people in Finland, France, Germany, Netherlands, Poland and Sweden, and operates its own production facility in Vantaa.
About Taaleri Bioteollisuus
Subscribe to releases from Taaleri Bioteollisuus
Subscribe to all the latest releases from Taaleri Bioteollisuus by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Taaleri Bioteollisuus
Taaleri Bioteollisuus sijoittaa kierrätysbetonin jalostusyhtiö C2CA:han13.11.2024 09:07:00 EET | Tiedote
TAALERI BIOTEOLLISUUS LEHDISTÖTIEDOTE 13.11.2024 KLO 9:07 Taaleri Bioteollisuus sijoittaa kierrätysbetonin jalostusyhtiö C2CA:han Taaleri Bioteollisuus I -rahasto sijoittaa alankomaalaiseen C2CA Technology B.V. -yhtiöön, joka on kierrätysbetonin jalostaja. Investointi mahdollistaa kaupallisen kokoluokan tuotantolaitoksen rakentamisen Alankomaiden Rotterdamiin. Valmistuessaan tuotantolaitos käsittelee 150 000 tonnia purkubetonia vuodessa. C2CA on kehittänyt menetelmän, joka mahdollistaa purkubetonin käytön osana uuden betonin valmistusta. Innovatiivisen prosessin ansiosta sellaista betonia, joka tavanomaisessa käytössä on tullut elinkaarensa loppuun, pystytäänkin jatkojalostamaan. Mekaanisen prosessin ja lämmön avulla purkubetoni voidaan erotella peruskomponenteiksi, kuten kiviainekseksi, hiekaksi ja sementiksi. Lisäksi prosessin avulla sementtijae jatkojalostetaan, mikä mahdollistaa kierrätysjakeen käytön uuden betonin valmistuksessa. C2CA:n kierrätettyjä materiaaleja on hyödynnetty ku
Taaleri Bioindustry invests in C2CA, a company upcycling waste concrete13.11.2024 09:07:00 EET | Press release
TAALERI BIOINDUSTRY PRESS RELEASE 13 NOVEMBER 2024 AT 9:07 (EET) Taaleri Bioindustry invests in C2CA, a company upcycling waste concrete Taaleri Bioindustry Fund I is investing in C2CA Technology B.V., a Duch company and the technological leader in waste concrete upcycling. The investment will enable the construction of a full-scale commercial production facility in Rotterdam, in the Netherlands. The factory will process approximately 150,000 tonnes of waste concrete annually. C2CA has developed a process that allows upcycling of end-of-life concrete into drop-in materials for use in new concrete. The innovative process enables the effective separation of the individual components of end-of-life concrete (aggregate, sand and cement paste) through the combination of mechanical and thermal processes. C2CA's upcycled materials have been used in six reference construction projects under the Dutch Climate Envelope initiative, showcasing their quality and performance in real-world applicatio
Taalerin bioteollisuusrahasto sijoittaa sieniproteiinia valmistavaan Eniferiin23.5.2024 08:45:00 EEST | Tiedote
TAALERI BIOTEOLLISUUS LEHDISTÖTIEDOTE 23.5.2024 KLO 8.45 Taalerin bioteollisuusrahasto sijoittaa sieniproteiinia valmistavaan Eniferiin Taalerin bioteollisuuteen keskittyvä Bioteollisuus I -rahasto sijoittaa suomalaiseen sieni- eli mykoproteiinia valmistavaan Eniferiin. Sijoitus mahdollistaa uuden tuotantolaitoksen rakentamisen Kantvikiin Kirkkonummelle. Enifer perustettiin vuonna 2020 patentoidun PEKILO®-teknologian jatkokehittämistä ja kaupallistamista varten. Mykoproteiinin valmistuksessa hyödynnetään fermentointiprosessia, joka kehitettiin Suomessa alun perin 1970-luvulla. Nykyinen valmistustapa muistuttaa oluen tai soijan fermentointiprosessia. Eniferin mykoproteiini on kestävä vaihtoehto eläin- ja kasviproteiineille. Vaihtoehtoinen proteiininlähde edesauttaa biodiversiteetin säilymistä, sillä tuotanto ei vaadi maankäyttöä ja lisää sitä epäsuorasti vain vähän. Enifernin mykoproteiinilla on matala hiili- ja vesijalanjälki verrattuna eläin- ja kasviproteiineihin. PEKILO®-mykoproteii
Taaleri’s bioindustry fund invests in Enifer, a company producing mycoprotein23.5.2024 08:45:00 EEST | Press release
TAALERI BIOINDUSTRY PRESS RELEASE 23 MAY 2024 AT 8:45 (EEST) Taaleri’s bioindustry fund invests in Enifer, a company producing mycoprotein Taaleri Bioindustry Fund I invests in Enifer, a Finnish company producing fungi-based mycoprotein. Investment enables Enifer to construct a new mycoprotein factory in Kantvik, Kirkkonummi, Finland. Enifer was founded in 2020 to develop and commercialize the proprietary PEKILO® technology further. Mycoprotein is produced by cultivating a specific species of fungus in a fermentation process that is not too distinct from brewing beer or making soy sauce. The PEKILO® fermentation process was originally developed in Finland in the 1970s and used by the forest industry. Mycoprotein is a sustainable alternative to animal and some soy proteins. This alternative protein has a significant positive contribution to biodiversity because the production process does not require direct land use as many other plant and animal proteins do. The production of mycoprote
Taaleri’s bioindustry fund invests in Nordic Bioproducts Group, a company producing cellulose-based materials with a high processing value30.3.2023 09:15:00 EEST | Press release
TAALERI BIOINDUSTRY PRESS RELEASE 30 MARCH 2023 AT 9:15 (EEST) Taaleri’s bioindustry fund invests in Nordic Bioproducts Group, a company producing cellulose-based materials with a high processing value Taaleri’s bioindustry fund invests in Nordic Bioproducts Group, a Finnish company producing cellulose-based materials with a high processing value. The purpose of the investment is to strengthen Nordic Bioproducts Groups’s (NBG) growth and expansion. Nordic Bioproducts Group was founded in 2019 to develop new biomaterials based on the patented AaltoCell technology. The cellulose hybrids developed and manufactured by NBG are processed from Finnish forest fibres and cellulose-containing industrial and agricultural side and waste streams. The company aims to bring to the market environmentally more sustainable and low-emissions alternatives to fossil raw materials and harmful chemicals. For example, in the textile industry, pulp-based fibres can replace cotton and artificial fibres, and in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom